Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib, Cetuximab, and Camrelizumab (VCC) in BRAF V600E/MSS mCRC
NCT05019534Phase 1Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vemurafenib, cetuximab and camrelizumab in metastatic colorectal cancer (mCRC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Tolerability and Safety and Recommended Phase 2 Dose. Status: unknown.
02
Drugs
vemurafenibcetuximabcamrelizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05019534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019534.